Dose EscaLation to Intraprostatic tumour Nodules in localisEd prostATE cancer: A phase II study examining the toxicity and feasibility of a dose escalated boost to a magnetic resonance imaging identified tumour nodule or nodules in localised prostate cancer | Not Recruiting
Dose EscaLation to Intraprostatic tumour Nodules in localisEd prostATE cancer: A phase II study examining the toxicity and feasibility of a dose escalated boost to a magnetic resonance imaging identified tumour nodule or nodules in localised prostate cancer
DELINEATE
Trial Source

There is no location for this trial

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Health Conditions
  • Topic: National Cancer Research Network
  • Subtopic: Prostate Cancer
  • Disease: Prostate
Primary Contact Details
Not Recruiting
Recruitment Status
ISRCTN04483921
Primary Trial ID Number
Summary
http://cancerhelp.cancerresearchuk.org/trials/a-study-looking-at-increasing-dose-of-radiotherapy-to-areas-of-cancer-inside-prostate-gland-delineate
Research Details
  • Dose Escalation to Intra-prostatic Tumour Nodules in Localised Prostate Cancer To assess the toxicity and feasibility of a dose escalated intensity-modulated radiotherapy boost to tumour nodules within the prostate using anatomical and functional magnetic resonance (MR) imaging to identify tumour. The aim is to maintain current levels of late toxicity.
Phase
Phase II
Study Design
Non-randomised; Interventional; Design type: Process of Care, Treatment
Study Type
Interventional
Intervention

100 patients to be recruited and have MRI scans to diagnose intra-prostatic tumour nodules. 50% of patients expected to have lesions and so 50 patients to be treated with a radiotherapy boost Radiotherapy boost: A dose escalated external beam radiotherapy boost to intraprostatic tumour nodules within the prostate gland; Follow Up Length: 60 month(s); Study Entry : Registration only

Intervention Type
Other
Primary Outcome Measures
  • Late rectal toxicity; Timepoint(s): 12 months
Secondary Outcome Measures
  • 1. Acute genitourinary (Gu) and gastrointestinal (GI) toxicity; Timepoint(s): 18 weeks
  • 2. Biochemical Recurrence; Timepoint(s): 24 months
  • 3. Late GU and GI toxicity; Timepoint(s): 12 months and 24 months
  • 4. Quality of Life Scores; Timepoint(s): 24 months
Publication(s)
Sorry, this information is not available
Result Reports
Sorry, this information is not available
Gender
Male
Age Range
Adult
Who Can Participate
Patient
Number of Participants
Planned Sample Size: 100; UK Sample Size: 100
Participant Inclusion Criteria
  • 1. Age more than or equal to 18 years
  • 2. Histologically confirmed adenocarcinoma of the prostate
  • 3. National Collaborative Cancer Network+ (NCCN) risk groups intermediate or high risk localised prostate cancer
  • 4. Normal blood count [haemoglobin (Hb) > 11g/dl, white blood cell (WBC) > 4000/mm³, platelets > 100,000/mm³]
  • 5. World Health Organisation (WHO) performance status 0 or 1
  • 6. Life expectancy of 10 years or more
  • 7. Written informed consent
  • 8. Patients must be prepared to attend follow-up
  • 9. For template biopsy sub-study must be considered fit for general / spinal anaesthetic; Target Gender: Male ; Lower Age Limit 18 no age limit or unit specified
Participant Exclusion Criteria
  • 1. Prior radiotherapy to the prostate or pelvis
  • 2. Bilateral hip replacement
  • 3. Prior hormone therapy
  • 4. Radical prostatectomy
  • 5. Lymph Node Risk > 30%
  • 6. National Collaborative Cancer Network+ (NCCN) Favourable Risk Group
  • 7. Evidence of seminal vesicle invasion, nodal or metastatic disease
  • 8. Any previous invasive cancer in the past 5 years, with the exception of non-melanoma skin cancer
  • 9. Patients with medical contraindication to magnetic resonance imaging (MRI) scanning
Trial Location(s)
Research Site
Sutton
Surrey
SM2 5PT
Trial Contact(s)
Primary Trial Contact
Ms Annie Gao
annie.gao@rmh.nhs.uk
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
United Kingdom
Scientific Title
Sorry, this information is not available
EudraCT Number
Sorry, this information is not available
Funder(s)
  • Cancer Research UK (CRUK) (UK)
Other Study ID Numbers
10309
Sponsor(s)
Institute for Cancer Research (UK)
Key Dates

Recruitment Start Date

13 Jul 2011

Recruitment End Date

20 Jul 2014

Trial Start Date

13 Jul 2011

Trial End Date

20 Jul 2014

Date Assigned

17 Aug 2011

Last Updated

18 Apr 2012